Drug Trial Radar · NCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Feb 4, 2026
Primary completion
Dec 12, 2028
Study completion Sep 30, 2031
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Dec 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Conditions
- Multiple Myeloma
Interventions
JNJ-79635322Drug
JNJ-79635322 will be administered as SC injection.
TeclistamabDrug
Teclistamab will be administered as SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall ResponseTime frame: Up to 5 years and 7 months
- Progression-Free Survival (PFS)Time frame: Up to 5 years and 7 months
Locations
157 sites in 15 countries. Site status is shown where the registry gives one.
Mayo Clinic Phoenix
Phoenix, Arizona · Recruiting
UAMS
Little Rock, Arkansas · Recruiting
City of Hope Duarte
Duarte, California · Recruiting
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UCLA Medical Center
Los Angeles, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
Colorado Blood Cancer Institute
Denver, Colorado · Recruiting
University of Connecticut Health Center
Farmington, Connecticut · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
Florida Cancer Specialists & Research Institute
Fort Myers, Florida · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
University of Miami Hospital
Miami, Florida · Recruiting
Moffit Cancer center
Tampa, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
City of Hope Chicago
Zion, Illinois · Recruiting
University of Iowa Hospital and Clinics
Iowa City, Iowa · Recruiting
Mission Cancer Blood
Waukee, Iowa · Recruiting
University of Kansas Cancer Center
Kansas City, Kansas · Recruiting
Norton Cancer Institute
Louisville, Kentucky · Recruiting
University of Maryland School of Medicine
Baltimore, Maryland · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Boston University Medical Center
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Mount Sinai Brooklyn
Brooklyn, New York · Recruiting
NYU Winthrop
Mineola, New York · Recruiting
Mount Sinai Chelsea
New York, New York · Recruiting
Laura and Isaac Perlmutter Cancer Center NYU ACC
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of North Carolina
Chapel Hill, North Carolina · Recruiting
Durham VAMC
Durham, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Oregon Health And Science University
Portland, Oregon · Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania · Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Showing 40 of 157 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.